Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

34.57
-2.1100-5.75%
Post-market: 34.50-0.0700-0.20%19:54 EDT
Volume:2.95M
Turnover:103.20M
Market Cap:9.68B
PE:19.64
High:36.45
Open:35.80
Low:34.48
Close:36.68
Loading ...

Company Profile

Company Name:
Exelixis
Exchange:
NASDAQ
Establishment Date:
1994
Employees:
1147
Office Location:
1851 Harbor Bay Parkway,Alameda,California,United States
Zip Code:
94502
Fax:
650 837 8300
Introduction:
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Directors

Name
Position
Michael M. Morrissey
Director,President and Chief Executive Officer
Stelios Papadopoulos
Chairman of the Board
Alan M. Garber
Director
Carl B. Feldbaum
Director
Charles Cohen
Director
George A. Scangos
Director
George Poste
Director
Jack L. Wyszomierski
Director
Julie A. Smith
Director
Lance Willsey
Director
Vincent T. Marchesi
Director

Shareholders

Name
Position
Michael M. Morrissey
Director,President and Chief Executive Officer
Christopher J. Senner
Executive Vice President and Chief Financial Officer
Patrick J. Haley
Senior Vice President, Commercial
Gisela M. Schwab
President, Product Development and Medical Affairs and Chief Medical Officer
Jeffrey J. Hessekiel
Executive Vice President, General Counsel and Secretary
Peter Lamb
Executive Vice President, Scientific Strategy and Chief Scientific Officer